NCT06389526View on ClinicalTrials.gov

A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 15, 2025

Primary Completion Date

May 30, 2028

Study Completion Date

May 30, 2028

Conditions
Advanced or Metastatic Solid Tumors
Interventions
BIOLOGICAL

CHS-1000

Specified dose on specified days

BIOLOGICAL

Toripalimab

Specified dose on specified days

Sponsors
All Listed Sponsors
lead

Coherus Oncology, Inc.

INDUSTRY

NCT06389526 - A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter